CardioDx Honored as 2012 Gold Edison Award Winner Corus CAD Wins at the Edison Awards Gala; Awards Celebrate 25 Years of Honoring Innovators and Innovation
PALO ALTO, Calif. – April 30, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that Corus® CAD has been honored as a gold winner in the Science & Medical category of the internationally-renowned 2012 Edison Awards. The awards, which were presented last week at a gala in New York, symbolize the innovation personified by Thomas Alva Edison, inspiring America’s drive to remain at the forefront of creativity and ingenuity in the global economy.
“As the pace of innovation quickens and the ‘race to next’ becomes ever more competitive, it’s increasingly important to take a moment out of our hectic lives to recognize excellence in innovation and greatness in the teams of innovators who make our future. We are honored to present CardioDx with an Edison Award as one of the leading innovators of today and tomorrow,” said Thomas Stat, 2012 Edison Awards Steering Committee Chairman.
“We are pleased that the Edison Awards judges have recognized the innovation of Corus CAD, adding to a growing list of accolades for the test,” said David Levison, president and CEO of CardioDx. “Clinicians also are increasingly recognizing the clinical utility of Corus CAD as a means to reduce unnecessary procedures and radiation exposure, with more than 25,000 tests ordered to date.”
With a simple blood draw, Corus CAD can help primary care clinicians and cardiologists exclude obstructive coronary artery disease as the cause of a stable, non-diabetic patient's symptoms. It is the first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. The test is safe and does not expose patients to radiation risks or imaging agent intolerance.
Corus CAD has also been honored as a winner of The Wall Street Journal’s Technology Innovation Awards and one of TIME’s Top Ten Medical Breakthroughs. The ballot of nominees for the Edison Awards is judged by more than 3,000 senior business executives and academics from across the nation whose votes acknowledge the Finalists’ success in meeting the award criteria of Concept, Value, Delivery and Impact.
Winners of the awards for each category were announced on April 26, 2012 at the Edison Awards Annual Gala, held in the historic ballroom of New York’s famed Capitale.
The members of the Edison Awards Steering Committee are senior executives with diverse marketing, scientific, and business backgrounds who monitor the development and successful launch of innovative products each year. The Committee is responsible for bestowing the annual Edison Achievement Awards and serves as a guidepost in developing the list of nominees that is presented to the Edison Award judges.
The 2012 Edison Awards are sponsored by Nielsen, Discovery Communications, Science Channel, USA Today, CSRware, and applepeak. For more information about the Edison Awards and a full list of winners, visit www.edisonawards.com.
CAD The Corus CAD test measures the RNA levels of 23 genes from a whole blood sample. Because these RNA levels are altered when obstructive coronary artery disease is present, the Corus CAD score aids clinicians in assessing whether an individual patient’s symptoms may be due to obstructive coronary artery disease.
Corus CAD is commercially available through an innovative patient sample kit that includes everything needed for blood collection and express delivery to the company’s CLIA-certified Palo Alto, Calif. laboratory. Test results are delivered promptly to the clinician’s office. Corus CAD is currently available in the United States.
For more information please visit http://www.cardiodx.com/media-kit/.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.